

ReMind^{UK}

Dementia research,
diagnosis and support

Clinical Trials
2014 – 2026

2014 RICE/14/06/Elan Extension	A 12-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
2014 RICE/14/07/TauRx Extension	An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia
2014 RICE/14/08/Pfizer	A Randomized, 18-Week, Placebo Controlled, Double Blind, Parallel Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil.
2014 RICE/14/09/BI 1289.7	Study 1289.7: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 once or twice daily during a 12-week treatment period compared to donepezil and placebo in patients with mild Alzheimer's Disease.
2015 RICE/15/03/AC Immune	A Phase I Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability and Immunogenicity of ACI-35 in Patients with Mild to Moderate Alzheimer's Disease.
2015 RICE/15/04/Lilly Solanezumab Extension	Eli Lilly H8A-MC-LZAX(b) study
2015 RICE/15/05/Biogen ENGAGE	Phase 3 Efficacy and Safety Study of BIIB037 in subjects with Early Symptomatic Alzheimer's Disease

2015 RICE/15/08/Axovant	A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease.
2016 RICE/16/01/BI 1289.5	Study 1289.5 Phase II: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 once or twice daily during a 12-week treatment period compared to placebo in patients with prodromal Alzheimer's Disease.
2016 RICE/16/02/Generation	A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease.
2016 RICE/16/03/ACADIA	A Double-Blind, Placebo-Controlled Study to examine the safety and efficacy of Pimavanserin for the treatment of Agitation and Agression in Alzheimer's disease.
2016 RICE/16/07/XanADu	XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 35mg Twice Daily Xanamem™ in Subjects with Mild Dementia due to Alzheimer's disease.
2016 RICE/16/08/Lilly LMDD	Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease.
2016 RICE/16/10/Axovant Extension	A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer's Disease
2017 RICE/17/02/CREAD2	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease.
2017 RICE/17/03/Eisai MISSION	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-month study to evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease
2017 RICE/17/04/Avanir	A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment

	of agitation in patients with dementia of the Alzheimer's type.
2017 RICE/17/05/ACADIA Harmony	A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
2017 RICE/17/06/Generation2	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
2017 RICE/17/01/ACADIA Extension	A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease
2018 RICE/18/03/Graduate2	A Phase III, Multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of Gantenurumab in patients with early (prodromal to mild) Alzheimer's disease
2018 RICE/18/04/AC Immune	A Phase II Double-blind, randomized, placebo-controlled, adaptive-design study to assess the safety, tolerability, immunogenicity and target engagement of ACI-24 formulations in patients with mild Alzheimer's disease.
2018 RICE/18/07/Julius	A Phase 2a, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild cognitive impairment due to Alzheimer's diseases or mild Alzheimer's diseases
2019 RICE/19/01/AC Immune	A Phase Ib/Ila Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects with Early Alzheimer's Disease
2020 RICE/20/01/Biogen EMBARK	Phase 3b open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer's disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205
2020 RICE/20/03/AUTONOMY	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease

2021 RICE/21/01/Postgraduate	Postgraduate: An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants with Alzheimer's disease
2021 RICE/21/02/EVOKE	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE)
2021 RICE/21/03/EVOKE+	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE plus)
2022 RICE/22/03/TOPHAT	Trial of Ondansetron as a Parkinson's Hallucination Treatment
2022 RICE/22/06/ImmunoBrain	ImmunoBrain: A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease
2023 RICE/23/05/ReTain	Janssen ReTain: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease
2024 RICE/24/01/TRAILBLAZER	Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
2024 RICE/24/03/TargetTau-1	A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease (TargetTau-1)
2024 RICE/24/04/LAKI	A Study of Remternetug Versus Placebo in Early Alzheimer's Disease: Participants at Risk for Cognitive and Functional Decline
2024 RICE/24/05/MK-1167	A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer's Disease Dementia

2024 RICE/24/06/TRONTIER2	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Trontinemab in Patients with Early Alzheimer's disease (MCI to Mild Dementia due to AD)
2025 ReMindUK/25/03/MK-2214	A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease
2026 ReMindUK/26/01/TREMHANCE	A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 48-week SAR448851 treatment followed by open-label extension in participants with early Alzheimer's disease
2026 ReMindUK/26/02/AROMAPT	A Phase 1/2A placebo-controlled dose escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MAPT-SC in healthy subjects and subjects with Early Alzheimer's disease
2026 ReMindUK/26/03/SPINOZA	A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)